NEW
YORK, June 14, 2023 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders
of Fulcrum Therapeutics, Inc..
Shareholders who purchased shares of FULC during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/fulcrum-loss-submission-form/?id=40743&from=4
CLASS PERIOD: March 3, 2022
to March 8, 2023
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (i) the
preclinical data submitted in support of FTX-6058 (an
investigational oral fetal hemoglobin inducer for the treatment of
sickle cell disease and other hemoglobinopathies) showed safety
concerns regarding potential hematological malignancies; (ii) the
foregoing safety concerns increased the likelihood that the FDA
would place a clinical hold on preclinical studies of FTX-6058;
(iii) accordingly, the Company had overstated FTX-6058's clinical
and/or commercial prospects; and (iv) as a result, the Company's
public statements were materially false and misleading at all
relevant times.
DEADLINE: June 27, 2023
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/fulcrum-loss-submission-form/?id=40743&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of FULC during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is June 27, 2023. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law
Firm is committed to ensuring that companies adhere to responsible
business practices and engage in good corporate citizenship. The
firm seeks recovery on behalf of investors who incurred losses when
false and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-fulcrum-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-june-27-2023--nasdaq-fulc-301850091.html
SOURCE The Gross Law Firm